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Background: Individuals diagnosed with serious mental illnesses are at increased risk of obesity- and
cardiovascular-related morbidity and early mortality. Lifestyle interventions aimed at weight loss, even those
adapted to suit the needs of this particular subgroup, have rarely produced clinically meaningful reductions in
weight.
Methods/design: The STRIDE study is a multi-site, parallel, two-arm randomized controlled translational trial.
Participants were recruited from community mental health clinics and an integrated not-for-profit health system.
Participants were randomized either to usual care or to a 12-month intervention that consisted of: 1) weekly group
participation for six months covering topics on nutrition, physical activity and lifestyle changes; 2) monthly group
participation for an additional six month maintenance period; and 3) individual monthly contacts from intervention
group facilitators during the second six month phase. All participants are assessed at baseline, 6, 12, and 24 months
post-enrollment. Process and implementation evaluations are included and the study design includes a cost-utility
analysis. Participants include 200 individuals with serious mental illness with an average age of 47.1 years, a mean
body-mass index of 38.3 kg/m2 and taking an average of 3.2 psychiatric medications at baseline. Baseline physiological
measures included mean blood pressure (SBP/DBP) measurements of 119.2 (SD = 14.7)/79.4 (SD = 10.1); 35% reported a
hypertension diagnosis and 11% took antihypertensive medications. Average lipid levels (mg/dL) were: a) triglycerides
188.0 (SD = 138.6), ranged from 43 to 1145; b) LDL 101.4 (SD = 32.9) and ranged from 17 to 185; c) HDL 45.8 (SD = 12.7)
and ranged from 22 to 89; and d) total cholesterol 181.6 (SD = 39.7) and ranged from 50 to 324. Average fasting
glucose levels were 108.9 (SD = 32.5) and ranged from 24 to 289. Average fasting insulin levels were 13.0 (SD=11.9)
and ranged from 2 to 99.
Discussion: The STRIDE study is based on a modified version of the PREMIER comprehensive lifestyle intervention,
DASH diet arm. STRIDE has successfully enrolled 200 individuals with serious mental illness in community-based
settings. Baseline characteristics present a population at high risk for obesity-related negative health outcomes and
demonstrate the need for evidence-based interventions to reduce these risks.
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Individuals with serious mental illnesses are at greatly
increased risk of a number of medical comorbidities
including obesity [1], metabolic syndrome [2-4], diabetes
mellitus [4-6], and subsequent early mortality [7-9],
primarily from cardiovascular disease [2,10,11]. The
causes of these elevated cardiometabolic risks can include
factors such as poor access to medical care [12,13], poor
nutrition [14], sedentary lifestyle [11], and smoking [11,15]
but they can also be exacerbated by the antipsychotic
agents prescribed to treat mental health conditions
[16-23]. Because many individuals diagnosed with serious
mental illnesses rely on antipsychotic medications as a
primary component of their treatment, complementary
treatments that reduce weight gain and potentially reduce
associated cardiometabolic risks have been suggested by
clinicians and researchers [1]. Such treatments appear
feasible [24,25] and valued by potential recipients [25] but
their effectiveness has been inconsistent and, when effect-
ive, weight losses have been modest [26]. Bartels and
Desilets found that manualized lifestyle health promotion
programs lasting more than 3 months—combining activ-
ities with education, emphasizing weight management
through improved nutrition and physical exercise—pro-
mote success but nevertheless only result in clinically
significant weight loss for a minority of individuals [26].
Community-based approaches which improve the magni-
tude of weight loss and physical fitness are needed as well
as interventions that reduce cardiometabolic risks, e.g.,
blood pressure, insulin resistance, or lipid levels.
This protocol describes a randomized controlled trial
assessing the effectiveness of translating a known effica-
cious and comprehensive lifestyle intervention, adapted
for individuals with serious mental illnesses at high risk
for obesity, diabetes, and cardiovascular disease, and re-
ceiving community-based treatment, including anti-
psychotic medications, for their mental health disorders.
Methods/design
The STRIDE study is a parallel-arm, multi-site, random-
ized controlled trial, translating the PREMIER comprehen-
sive lifestyle intervention [27-30] DASH diet arm [31] for
individuals taking antipsychotic medications. The primary
aims are to test the hypotheses that the intervention is
more effective than usual care in: 1) reducing weight and
body mass index (BMI); 2) reducing fasting insulin levels
and increasing insulin sensitivity; and 3) reducing total
cholesterol and LDL cholesterol at 6, 12, and 24 months.
Secondary aims are to explore the effects of exercise moti-
vation, dietary motivation, social support and weight loss
expectations on primary outcomes, and to examine the
moderating effects of ethnicity, gender, mental health diag-
nostic group, medication type, and metabolic syndrome.
Process and implementation evaluations are designed toidentify facilitators and barriers of behavior change among
participants; a cost-utility analysis will provide economic
information for program planners considering adoption.
Settings
To increase clinical relevance and the likelihood of future
adoption, implementation, and sustainability of the inter-
vention, we limited our exclusion criteria and worked with
community partners to deliver the intervention in routine
care settings. Our partners include two community mental
health centers—Cascadia Behavioral Healthcare (Cascadia)
and LifeWorks Northwest (LifeWorks)—and Kaiser
Permanente Northwest (KPNW), a not-for-profit inte-
grated health system. Cascadia serves approximately
12,000 low-income clients by providing outpatient mental
health care and addiction treatment services across three
Oregon counties. LifeWorks serves the mental health and
addiction treatment needs of approximately 16,000 clients
annually in 22 clinics throughout the greater Portland,
Oregon metropolitan area. The majority of these clients
come from impoverished and underserved segments of
the population. KPNW provides comprehensive medical,
mental health and addiction treatment to an insured
population of about 480,000 members in northwest
Oregon and southwest Washington. All study procedures
were reviewed, approved, and are monitored by the Kaiser
Permanente Northwest Institutional Review Board (other
participating sites ceded authority to KPNW). All partici-
pants were informed of their rights and responsibilities as
research participants and provided written informed
consent prior to enrollment.
Participants
Our sample includes individuals age ≥18 who were
taking antipsychotic agents at study enrollment and who
were overweight or obese (defined as BMI ≥ 27). We
asked prescribing clinicians to review records for poten-
tial participants to ensure that they did not have medical
or psychiatric conditions that precluded participation in
a lifestyle and weight loss program that included changes
to dietary practices and promotion of moderate exercise.
We excluded individuals with cognitive impairment suf-
ficient to interfere with their ability to provide informed
consent, complete study questionnaires, or participate in
a group intervention. We excluded women who were
pregnant, breastfeeding, or planning a pregnancy during
the study because reduced calorie intake may be contra-
indicated. We also excluded people with a bariatric
surgery history or a wasting illness (e.g., cancer) because
they are at increased risk for weight loss as a result
of their medical status. Finally, we excluded individuals
currently enrolled in another weight reduction program
as inclusion could confound the results of our
intervention.
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Using administrative and clinical databases at two sites
(KPNW, Cascadia) and mental health clinician referral
at the third site (LifeWorks), we identified potential
study participants on the basis of their medication use,
diagnoses, and current BMI. A personalized study invita-
tion letter was prepared for each potential participant
and sent to their primary care provider, psychiatrist, or
psychiatric nurse practitioner, to review for suitability
for the study and to co-sign if appropriate. Clinicians
returned letters to study staff for mailing to potential
participants. The letters provided details about the study,
a toll-free study phone number, and a prepaid postcard
to indicate interest in participating or to decline further
contact. Letters were followed with phone calls by study
recruitment staff who provided additional study details,
answered questions, and conducted a brief screening.
Those who met preliminary qualifications for the study
were scheduled for the first screening visit.
At the first screening visit, potential participants
attended a group orientation session where they received
an overview of the study and had a chance to ask
questions. Those who remained interested consented to
having their height and weight measured. BMI was then
calculated, inclusion and exclusion criteria reviewed, and
eligibility established. Eligible participants completed a
questionnaire and scheduled a second screening and
randomization visit at which a baseline fasting blood
specimen was drawn.
At the second screening visit, participants arrived having
fasted for at least eight hours, had their blood drawn and
their blood pressure and waist circumference measured.
Individuals who had not been fasting were rescheduled.
All individuals received reminder post-cards prior to the
visit that included fasting and medication instructions (i.e.,
directions to postpone taking diabetes medications until
after the fasting blood draw) and asking them to wear
loose clothing to aid measurements. Participants also re-
ceived reminder telephone calls the day before the visit.
Following the blood draw, participants were provided with
a snack and asked to take any medications at that time if
they could not do so prior to the blood draw. They were
then randomized to either intervention or usual care
groups using a blocked, stratified procedure to ensure that
group assignments remained balanced across gender and
baseline BMI (27–34.9 and ≥ 35) within each site. Clinic
staff involved in collecting data were blinded to participant
assignment. Once group assignment was determined,
non-clinic staff informed the participant and provided
appropriate information about upcoming study activities.
Intervention participants were notified when the group
intervention was expected to begin; usual care participants
were scheduled for the first follow up assessment, e.g. after
6 months. Usual care participants had no other obligationto the study and were free to initiate any weight loss effort
on their own. We assessed all self-reported weight loss
efforts at each follow-up for both the intervention and
usual care participants.
Tailored lifestyle intervention
The STRIDE intervention was based on the NHLBI-
funded PREMIER lifestyle intervention, DASH diet arm
[30]. It was designed to promote weight loss and reduce
obesity-related risks, including diabetes risk, through
dietary changes, moderate calorie reduction, and increased
energy expenditure. Intervention targets were based on
clinical practice guidelines established for obesity treat-
ment for individuals at increased risk for cardiovascular
disease [32,33]. The intervention built upon prior research
[27], behavior change theories [34,35], and motivational
theory [36-39] to enhance self-efficacy and promote long-
term behavior change. Adaptations to content and imple-
mentation made specifically to suit this population have
been described elsewhere [25]. The STRIDE intervention
manual is available for download [40].
STRIDE began with a 6-month intensive group counsel-
ing phase followed by a less-intensive 6-month mainten-
ance phase that included both group and individual
contacts. Throughout both phases, implementation strat-
egies included: frequent contacts, participant-centered
group and individual facilitation approaches, and indi-
vidual contacts that tailored the intervention to the parti-
cipant’s preferences (as components of group meetings
and separately, when needed). The program also targeted
participants’ readiness to change, and encouraged group
interactions that facilitated problem solving and social
support, provided support for appropriate goal setting,
and facilitated the acquisition of new information and
skills for behavior change. Group leaders presented exam-
ples of behavioral options and used decisional balance
approaches [41] to assist participants in moving toward
action and setting new behavioral goals, paying careful
attention to the cultural appropriateness of the program
for minority participants. Sessions were designed to
actively engage participants in small-group activities that
fostered program ownership and allowed individual inter-
action with other participants and facilitators. Groups
were co-led by two facilitators with complementary back-
grounds; one with training as a mental health counselor,
the other with training in nutritional interventions, though
not a registered dietician. Having two interventionists
provided flexibility during group sessions, however, and
their differing backgrounds provided knowledge for
managing a full range of problems and questions. All in-
terventionists attended an initial two-day training meeting
on the general intervention approach, and an additional
two-day training meeting in the use of motivational
interviewing techniques. In Year 1, an additional one-day
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materials to individuals with mental illness, including
those with cognitive and literacy limitations. Follow-up
one-day trainings were held for all interventionists every
six months. Trainers also provided ongoing supervision
and individual training of all interventionists.
Intensive intervention (Phase 1)
The core of the intervention program was a series of
weekly group meetings designed to achieve a weight loss
of 4.5-6.8 kg (10–15 pounds) over a 6 month period.
Groups were two hours in length and included 20 -
minutes of physical activity (walking). Participants
received a STRIDE workbook with details on program
content, self-assessments and goal-setting procedures,
booklets for self-monitoring of food and activity, cooking
and meal planning guides with recipes, a copy of the
Calorie King book [42] to help them learn about the
calorie content of typical foods, and a resistance band
for strength training. Ancillary materials can be
downloaded at the study website [43].
Using a manualized protocol, facilitators promoted the
following specific strategies for achieving changes in
behavior, activity level, and weight: 1) self-monitoring of
diet and physical activity, 2) developing personalized diet
and physical activity plans, 3) moderately reducing
calories, 4) reducing portion sizes, substituting alternative
foods, and modifying meals so that they are lower in
calories and fat, 5) focusing on fruits and vegetables and
increasing low-fat dairy products and fiber intake (DASH
diet [44]), 6) increasing physical activity, 7) identifying
situations that trigger poor diet or physical activity
choices, and developing and rehearsing specific plans of
action to deal with those situations, and 8) graphing
behavioral progress and individual weight change.
Participants were encouraged to routinely monitor food
intake, calories, and physical activity; to set reasonable
short-term goals; formulate specific plans of action to
achieve those goals; and to develop reinforcement and
social support for carrying out each major element of the
plan. Participants were also asked to keep records of
servings of fruits and vegetables, servings of low-fat dairy
products, and sodium and fat intake. These records were
used by participants and interventionists to assess
progress. Because this program placed a strong emphasis
on increasing moderate-intensity physical activity, inter-
ventionists also helped participants determine how best to
fit physical activity into their daily lives, taking into
account each participant’s initial motivation, current
activity patterns, and weekly progress. The goal was to get
each participant to engage in 180 minutes per week, or
about 25 minutes per day, of moderate physical activity—
primarily walking. Participants were asked to record
minutes of physical activity each day, as well as hours slepteach night. Sleep hygiene was a module added to the ori-
ginal PREMIER intervention when modifications were
made for this population. Other modifications included
sessions focusing on stress management, advance planning
for anticipated episodes of mental illness, empowering
participants to engage in discourse with their prescribers
regarding their medication and weight-related concerns,
and tips on eating healthily on a restricted income.
Our experience has shown that willingness to make
behavior changes shifts frequently during long-term
weight loss intervention programs. Recognizing this real-
ity, intervention techniques allowed group facilitators to
help participants tailor weekly goals and action plans to
their current stage of change. Although general guide-
lines for intervention components were provided by the
interventionists (daily self-monitoring of caloric intake,
five or more days per week of physical activity, etc.), par-
ticipants were also encouraged to adjust their personal
goals and action plans each week to their immediate
situation, setting their own short-term goals each week
in consultation with the group facilitator. Participants
with no interest in physical activity were not forced to
set an exercise goal, although those who declined to set
a physical activity goal for several consecutive weeks
were encouraged to schedule an individual brief session
with the group facilitator who worked with them using
motivational interviewing techniques [38]. The objective
of this counseling session was to encourage reflection on
long-term goals, increase motivation to engage in more
physical activity, and address barriers to increased
activity.
Maintenance intervention (Phase 2)
Where the focus of Phase 1 was on weight loss and
acquisition of new information and behaviors, Phase 2
focused on maintaining weight loss through problem-
solving and motivational enhancement. Because previous
research has shown that greater frequency of contacts
between participants and providers improves mainten-
ance of weight loss [32], long-term obesity treatment
was a priority for the high-risk participants in this study.
At the same time, it is also important to recognize the
difficulty of maintaining the type of high-intensity
commitment required by Phase 1. Thus, Phase 2
consisted of one monthly group meeting to enhance
group problem solving and social support, and one low-
intensity individual session per month (by phone or
e-mail) to support participants’ individualized goals
without requiring time and travel to a group session.
In these individual contacts, participants set the agenda
and the facilitator and participants jointly reviewed the
participants’ diet and activity efforts for the previous
month, paying particular attention to barriers or
difficulties.
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Intervention and usual care groups were assessed at base-
line, 6, 12, and 24 months. Laboratory, physiological and
anthropometric measures were obtained at each assessment
and included: 1) height in meters measured to the nearest
0.1 cm (baseline only), 2) weight in kilograms measured to
the nearest 0.1 kg (body mass index was calculated as the
Quetelet index [kg/m2]), 3) waist circumference, measured
over participants’ underwear using inelastic tape at the
narrowest part of torso and measured in a horizontal plane
without compressing the skin, and 4) blood pressure, mea-
sured while participants were seated with legs uncrossed
and without talking after a 5-minute rest period, and then
again after an additional 30 second rest period. Blood was
drawn and all lab panels were collected after an overnight
(8–12 hour) fast. Tests included: 5) fasting insulin, 6)
fasting plasma glucose, 7) fasting triglycerides, and 8)
fasting cholesterol (total, HDL, LDL).
We followed the National Cholesterol Education
Program (NCEP) guidelines [45] and defined metabolic
syndrome as: Individuals with 3 or more of the following
risk factors: a) waist circumference greater than 102
centimeters in men or 88 centimeters in women; b)
triglycerides plasma level of 150 mg/dL or greater; c)
HDL-cholesterol plasma level less than 40 mg/dL for men
or less than 50 mg/dL for women (or taking cholesterol-
lowering medications); d) blood pressure of 130/85 mm
Hg or greater (or taking antihypertensive medications),
and/or e) fasting glucose greater than or equal to 110 mg/
dL (or taking glucose lowering medications).
To assess insulin resistance, we calculated the
Homeostasis Model Assessment Index for Insulin
Resistance (HOMA-IR) as follows: fasting glucose
[mmol/L] × fasting insulin [μU/mL]/22.5. This index
correlates very highly with the gold standard hyper-
insulinemic euglycemic clamp [46].
We included several self-reported measures to describe
participants and assess health and functional status and
medication use. These measures are shown in Table 1.
Data analysis
Effectiveness analyses of primary aims
We will use generalized estimating equations (GEE) [63]
to test the effectiveness of the intervention. GEE esti-
mates the population averaged model while accounting
for the correlation among observations as a result of
having multiple measures from the same person over
time. The primary coefficient of interest will be the time
by group (control vs. intervention) interaction, which
will indicate the degree of differential change across time
between the control and intervention groups. We will
include age and study site and time-invariant covariates.
Use of outcomes-related medications will be included as
time-varying covariates (e.g., controlling for metforminusage when testing intervention efficacy on diabetes
risk). The GEE models will be based on the normal distri-
bution with identity link, and the working covariance
matrix will be specified as exchangeable. An advantage of
GEE is that it is able to estimate models when data are
incomplete, assuming the data are missing at random and
the working covariance matrix is correctly specified [63].
This will allow us to include all participants according to
their initial group assignment in the analyses, which is
consistent with the intent-to-treat principle.
For every outcome, we will conduct a series of sensitivity
analyses by using transformations that improve the
normality of the outcome, using a different family and link
(e.g., negative binomial with log link) where appropriate,
and using an unstructured working covariance matrix.
Finally, we will also examine between-group differences
for various conceptualizations for the primary outcome of
weight, including percentage weight change, the propor-
tion of participants who are at or below his or her baseline
weight, and the proportion of participants who lose at
least 5% and 10% of their baseline weight. These will be
computed at all follow-up timepoints. These are not
intent-to-treat results, as these computations require that
data are not missing in order to compute the necessary
change scores for deriving these different measures of
weight. We will test the difference in percentage weight
change between the intervention and control groups using
a one-way ANCOVA, and test whether the proportion of
participants who are at or below their baseline weight at
follow-up is different between the arms using multiple
logistic regression. We will include age, site, and medi-
cations that are known to affect weight as covariates in all
analyses.
Analyses of secondary aims
We plan on examining the effects of exercise motivation,
dietary motivation, social support and outcomes expect-
ancies on weight change. We will also explore whether
ethnicity, gender, mental health diagnostic group, medica-
tion type, and metabolic syndrome moderates the treat-
ment effect on weight change. Furthermore, we will
examine whether there was an effect of the intervention on
patient reported outcomes including body image (Body
Weight, Image and Self-Esteem Evaluation Questionnaire -
B-WISE), psychiatric symptoms (Colorado Symptom
Index - CSI), quality of life (Wisconsin Quality of Life
Index - W-QLI), health-related self-efficacy (Patient Acti-
vation Measure - PAM), health (SF-36 general health
subscale), and functional status (Behavior and Symptom
Identification Scale - BASIS-24). Finally, we will evaluate
whether dose, defined as the number of intervention
sessions and number of telephone and email contacts, is
related to change in the outcomes across time among
participants who received the intervention.
Table 1 STRIDE measures and data collection schedule
BL 6 month 12 month 24 month
Physiologic measures
Height x
Weight x x x x
Body mass index (BMI) x x x x
Waist circumference x x x x
Blood pressure x x x x
Laboratory measures
Fasting insulin x x x x
Fasting plasma glucose x x x x
Fasting triglycerides x x x x






Education level x x x x
Medicaid status x x x x
Medicare disability status x x x x
Marital status x x x x
Employment status x x x x
Annual and monthly income x x x x
Number of individuals supported by income x x x x
Income source x x x x
SF-36 general health subscale [47-49] x x x x
Behavior and Symptom Identification Scale (BASIS-24) [50] x x x x
Colorado Symptom Index (CSI) [51,52] x x x x
Self-reported medications1 x x x x
Wisconsin Quality of Life Index (W-QLI) [53-55] x x x x
Patient Activation Measure (PAM) [56] x x x x
Body Weight, Image and Self-Esteem Evaluation Questionnaire (B-WISE) [57] x x x x
Social support scales for eating and exercise behavior [58] x x x x
Exercise confidence questionnaire [59] x x x x
Eating habits confidence questionnaire [59] x x x x
Weight outcome expectancies- ideal and goal weight [60,61] x x x x
7-day physical activity and sleep log [27] x x x x
7-day fruit and vegetable consumption [62] x x x x
Self-reported other efforts to lose weight x x x x
1Self-reported medications were also collected at 18 months.
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We used data from PREMIER DASH diet arm results [30]
to estimate power for repeated measures analysis of
variance for change in weight. We used repeated measures
ANOVA given the lack of well-established methods for
estimating power using GEE. Data were available forchange at 6 and 18 months. Because reported means and
standard deviations were based on completers alone, we
adjusted for attrition in our power analyses (although
primary analyses will be intent-to-treat). PREMIER
reported a 5.9% decrease in weight at 6 months for the
DASH diet group and a 1.6% decrease for control (advice
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case) attrition rate at six months, and alpha level of .05,
we have power of .96 to detect a significant group-by-time
interaction at 6 months. Using the 18-month values
(−1.6% for advice only, -4.4% for DASH) as a conservative
estimate for weight change at 12 months, we have power
of .87 for the group-by-time interaction term for weight
(assuming a 15% worst-case attrition rate). To estimate
power at 24 months, we assumed the same rate of weight
gain in the DASH group and weight loss from 6 to
18 months in the UC group, consistent with PREMIER.
For a 3.6% decrease from baseline in the DASH group and
1.8% decrease for UC at 24 months, we have power of .80
to detect a significant group-by-time interaction at
24 months, assuming 20% attrition. Power for waist cir-
cumference, fasting insulin, and insulin sensitivity were
based on data reported by Ard [31]. Power for total chol-
esterol, LDL, and HDL were based on data reported by
Obarzanek [64]. Only baseline and 6-month means were
available for these variables, so we have computed power
to detect a significant group-by-time interaction at
6 months only. For all variables, power exceeds .95 to de-
tect the group-by-time interaction.
Implementation and process evaluations
The implementation evaluation included observations of
organizational and other facilitators and barriers to im-
plementation; results of this evaluation are described
elsewhere [25]. Fidelity assessments documented adher-
ence to the intervention protocol and thus will allow
examination of implementation differences across
groups. Assessment of intervention fidelity includes both
qualitative and quantitative measures.
The study design also included a process evaluation
component, which sought to understand participants’
feelings toward, and responses to, the different elements
of the intervention and to lifestyle change more gener-
ally. Semi-structured interviews lasting approximately
30 minutes were conducted with participants at 3- (n =
38), 9- (n = 35), and 18-months (n = 29) following
randomization. Interviewers asked about barriers and fa-
cilitators of dietary and exercise changes. Of these, 76%
(n = 78) were conducted with intervention participants
and 24% (n = 24) with control participants. Interviews
were transcribed verbatim and coded using Atlas.ti. Ana-
lyses will identify themes related to lifestyle improve-
ments across participants; check coding will assess inter-
coder reliability.
Cost-utility analysis
The study was designed to conduct a cost-utility analysis
and includes estimates of the direct costs, per partici-
pant, of implementing the intervention. Relevant costs
for these analyses will include the resources necessary todeliver the intervention and the change in care costs
incurred by the organization that derive from the inter-
vention. We have included the EQ-5D [65], a brief,
self-administered, health-related quality of life measure
that assesses mobility, self-care, usual activities, pain/dis-
comfort, and anxiety/depression dimensions. Response
patterns yield 243 unique health states, and are commonly
used to generate a composite score or index reflecting the
preference value (utility) associated with a given health
state. We will calculate incremental cost-effectiveness
ratios for each intermediate trial outcome, and will further
report such a ratio for the improvement in mean EQ-5D
scores between the intervention and control groups.
Baseline characteristics
A total of 200 individuals with serious mental illnesses
were randomized to one of the treatment arms. Two
participants became ineligible after randomization, one
due to pregnancy and one due to an unspecified but ser-
ious health problem that caused repeated vomiting and
resulted in a significant weight loss. At baseline (Table 2),
participant diagnoses were affective psychosis (38%), bi-
polar disorder (32%), schizophrenia spectrum disorders
(29%) and PTSD (2%). Participants were taking an aver-
age of 3.2 psychiatric medications and 91% were taking
an atypical antipsychotic medication. Study participants
were an average age of 47.1 (SD = 10.7) years old. Thirty
percent were currently working and 35% reported being
disabled. About 31% of the sample had a high school
diploma, GED or less, and 43% were married or living
with a partner.
The sample had an average baseline weight of 107.7
kilograms (SD = 25.1), waist circumference of 113.9 centi-
meters (SD = 18.7), BMI of 38.3 (SD = 8.3) and 24% of the
sample reported a diabetes diagnosis. Differences between
observed weight and goal or ideal weights were 31.7
kilograms (SD = 18.5) and 38.2 kilograms (SD = 21.5)
respectively. Baseline physiological measures included
mean blood pressure (SBP/DBP) measurements of 119.2
(SD = 14.7)/79.4 (SD = 10.1); 35% reported a hypertension
diagnosis with 11% of people taking antihypertensive medi-
cations. Average lipid levels (mg/dL) were: a) triglycerides
188.0 (SD = 138.6), ranged from 43 to 1145; b) LDL 101.4
(SD = 32.9) and ranged from 17 to 185; c) HDL 45.8 (SD =
12.7) and ranged from 22 to 89; and d) total cholesterol
181.6 (SD = 39.7) and ranged from 50 to 324. Average
fasting glucose levels were 108.9 (SD = 32.5) and ranged
from 24 to 289. Average fasting insulin levels were 13.0
(SD=11.9) and ranged from 2 to 99. Psychiatric measures at
baseline include a mean CSI score of 19.3 (SD = 11.4,
possible scores range from 14–70 with higher scores indi-
cating more frequent symptoms), and a BASIS-24 mean
score of 1.37 (SD = 0.68, possible scores range from 0 to 4,
higher scores represent higher levels of difficulty in




Affective psychosis 75 (38)
Bipolar disorder 63 (32)
Schizophrenia spectrum disorder 58 (29)







Hispanic ethnicity 4 (2)
Education
Less than high school 15 (8)
High school graduate/GED 46 (23)
Some college/technical school 87 (44)
College graduate 37 (19)
Post graduate 15 (8)
Marital status
Never married 57 (29)
Widowed/Divorced/Separated 57 (29)
Married 69 (34)
Living with partner 17 (9)
Annual household income
$0 - $9,999 54 (28)
$10,000 - $29,999 58 (30)
$30,000 – $49,999 34 (17)
$50,000 or higher 49 (25)
Number of people supported by income, mean (SD) 2.0 (1.3)
Employment status
Currently working 59 (30)
Disabled 71 (36)
Retired, unemployed, student, homemaker, temporarily
laid off, or other
70 (35)
Atypical antipsychotic medication use 182 (91)
Medications taken that affect weight
≥1 that cause slight/moderate weight loss 77 (39)
≥1 that do not affect weight 168 (84)
≥1 that cause slight/moderate weight gain 21 (11)
≥1 that cause severe weight gain 128 (64)
Mood stabilizer medication use 97 (49)
Anti-depressant medication use 33 (17)
Smoked in the past year 65 (33)
Table 2 Baseline characteristics of the study participants












Waist circumference—cm.3 113.9 (18.7)
Body mass index4 38.3 (8.3)
Blood pressure: systolic—mmHg 119.2 (14.7)





Total cholesterol—mg/dL 181.6 (39.7)
Fasting glucose—mg/dL 108.9 (32.5)
Fasting insulinu—U/mL 13.0 (11.9)
Goal weight differential—kg.5 −31.7 (18.5)
Very likely to achieve goal weight, n (%) 33 (17)
Ideal weight differential—kg.6 −38.2 (21.5)
Very likely to achieve ideal weight, n (%) 21 (11)
Number of psychiatric medications 3.2 (1.5)
Psychiatric measures
CSI score7 19.3 (11.4)
BASIS-24 score8 1.37 (0.68)
SF36-GH score9 53.2 (21.3)
PAM13 (normed) score10 62.4 (16.0)
B-WISE score11 21.9 (3.6)
1Percentages reported use number of valid responses in the denominator.
Percentages may not sum to 100% because of rounding.
2Race and ethnic groups were self-reported.
3To convert values for weight to pounds, multiply kilograms by 2.2. To convert
values for centimeters to inches, multiply centimeters by 0.39.
4Body Mass Index is the weight in kilograms divided by the square of height
in meters.
5The difference between self-reported goal weight and observed weight
at baseline.
6The difference between self-reported ideal weight and observed weight
at baseline.
7Colorado Symptom Index.
8Behavior and Symptom Identification Scale 24-item version.
9SF-36 General Health Subscale.
10Patient Activation Measure.
11Body Weight, Image and Self-Esteem Evaluation Questionnaire (B-WISE).
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by the PAM score averaged 62.4 (SD = 16.0; scores between
55.2-67.0 are associated with beginning to take action in
managing one’s health). Body image, measured with the
B-WISE, averaged 21.9 (SD = 3.6, potential scores range
from 12–36 with higher scores indicating a more positive
body image).
Discussion
Though lifestyle interventions aimed at reducing weight
have been adapted for individuals with serious mental
illnesses, their effectiveness has been limited. Even effect-
ive interventions have only resulted in modest weight loss
for a minority of participants. There is a critical need for
more evidenced-based programs shown to benefit a greater
proportion of individuals, produce clinically meaningful
weight loss, reduce obesity-related cardiovascular risks,
and improve physical fitness. Moreover, it is important that
such interventions can be implemented in community-
based settings.
STRIDE is a lifestyle intervention modified for the unique
needs of overweight individuals taking antipsychotic
medications and delivered in community mental health
and integrated care settings. Despite the challenges of
implementing a rigorous weight reduction intervention in
any population, especially a population with SMI, we are
encouraged by our ability to recruit and retain participants
in STRIDE. To succeed in retaining individuals in the study
we employed several strategies for accommodating the life
circumstances of this disadvantaged population. We met in
several locations to minimize transportation, we provided
reminders prior to group meetings and study visits. We also
called individuals who missed group meetings and offered
make-up sessions.
This study was designed to test the effectiveness of
this intervention to reduce weight, fasting insulin levels,
total cholesterol and LDL cholesterol and increase insu-
lin. The study was also designed to explore potential me-
diators and moderators of the intervention’s effects, to
examine barriers and facilitators of behavior change, to
assess issues with implementing the intervention in this
population and to provide cost-effectiveness data in
order to inform future research and provide decision
makers with information needed for future program
adoption decisions. The results of this study will contrib-
ute to a better understanding of how to assist individuals
with mental illnesses to manage their weight and im-
prove their overall health.
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